Literature DB >> 19906894

Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Maria Luiza Silva1, Luçandra Ramos Espírito-Santo, Marina Angela Martins, Denise Silveira-Lemos, Vanessa Peruhype-Magalhães, Ricardo Carvalho Caminha, Péricles de Andrade Maranhão-Filho, Maria Auxiliadora-Martins, Reinaldo de Menezes Martins, Ricardo Galler, Marcos da Silva Freire, Rugimar Marcovistz, Akira Homma, Dirk E Teuwen, Silvana Maria Elói-Santos, Mariléia Chaves Andrade, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho.   

Abstract

Yellow fever (YF) vaccines (17D-204 and 17DD) are well tolerated and cause very low rates of severe adverse events (YEL-SAE), such as serious allergic reactions, neurotropic adverse diseases (YEL-AND), and viscerotropic diseases (YEL-AVD). Viral and host factors have been postulated to explain the basis of YEL-SAE. However, the mechanisms underlying the occurrence of YEL-SAE remain unknown. The present report provides a detailed immunological analysis of a 23-year-old female patient. The patient developed a suspected case of severe YEL-AVD with encephalitis, as well as with pancreatitis and myositis, following receipt of a 17D-204 YF vaccination. The patient exhibited a decreased level of expression of Fc-gammaR in monocytes (CD16, CD32, and CD64), along with increased levels of NK T cells (an increased CD3(+) CD16(+/-) CD56(+/-)/CD3(+) ratio), activated T cells (CD4(+) and CD8(+) cells), and B lymphocytes. Enhanced levels of plasmatic cytokines (interleukin-6 [IL-6], IL-17, IL-4, IL-5, and IL-10) as well as an exacerbated ex vivo intracytoplasmic cytokine pattern, mainly observed within NK cells (gamma interferon positive [IFN-gamma(+)], tumor necrosis factor alpha positive [TNF-alpha(+)], and IL-4 positive [IL-4(+)]), CD8(+) T cells (IL-4(+) and IL-5(+)), and B lymphocytes (TNF-alpha(+), IL-4(+), and IL-10(+)). The analysis of CD4(+) T cells revealed a complex profile that consisted of an increased frequency of IL-12(+) and IFN-gamma(+) cells and a decreased percentage of TNF-alpha(+), IL-4(+), and IL-5(+) cells. Depressed cytokine synthesis was observed in monocytes (TNF-alpha(+)) following the provision of antigenic stimuli in vitro. These results support the hypothesis that a strong adaptive response and abnormalities in the innate immune system may be involved in the establishment of YEL-AND and YEL-AVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906894      PMCID: PMC2812091          DOI: 10.1128/CVI.00369-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Age-related risk of adverse events following yellow fever vaccination in Australia.

Authors:  Glenda L Lawrence; Margaret A Burgess; Robert B Kass
Journal:  Commun Dis Intell Q Rep       Date:  2004

2.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

3.  Expanded programme on immunization (EPI). Inclusion of yellow fever vaccine in the EPI.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1996-06-14

4.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

5.  Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Authors:  Alena Y Khromava; Rachel Barwick Eidex; Leisa H Weld; Katrin S Kohl; Robert D Bradshaw; Robert T Chen; Martin S Cetron
Journal:  Vaccine       Date:  2005-05-09       Impact factor: 3.641

6.  Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis.

Authors:  A D Jennings; C A Gibson; B R Miller; J H Mathews; C J Mitchell; J T Roehrig; D J Wood; F Taffs; B K Sil; S N Whitby
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

7.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 8.  Yellow fever: an update.

Authors:  T P Monath
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

9.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

10.  Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.

Authors:  Jon L Belsher; Peter Gay; Margo Brinton; Joseph DellaValla; Robert Ridenour; Robert Lanciotti; Andrey Perelygin; Sherif Zaki; Christopher Paddock; Troy Querec; Tuofu Zhu; Bali Pulendran; Rachel B Eidex; Edward Hayes
Journal:  Vaccine       Date:  2007-09-18       Impact factor: 3.641

View more
  16 in total

1.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

Review 2.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

3.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

4.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

5.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

Review 6.  The COVID-19 Vaccine Landscape.

Authors:  Till Koch; Anahita Fathi; Marylyn M Addo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.

Authors:  Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

8.  Yellow fever virus vaccine-associated deaths in young women.

Authors:  Stephen J Seligman
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

9.  17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.

Authors:  Ana Carolina Campi-Azevedo; Luiza Pacheco de Araújo-Porto; Maria Luiza-Silva; Maurício Azevedo Batista; Marina Angela Martins; Renato Sathler-Avelar; Denise da Silveira-Lemos; Luiz Antonio Bastos Camacho; Reinaldo de Menezes Martins; Maria de Lourdes de Sousa Maia; Roberto Henrique Guedes Farias; Marcos da Silva Freire; Ricardo Galler; Akira Homma; José Geraldo Leite Ribeiro; Jandira Aparecida Campos Lemos; Maria Auxiliadora-Martins; Iramaya Rodrigues Caldas; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

Review 10.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.